SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
658[Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and anttuck-2/18/2006
657Item 1.01 Amendment of a Material Definitive Agreement. In connection with his Icebrg-2/17/2006
656>> Often a precursor to a merger << CEO is gone.scaram(o)uche-2/14/2006
655CFO leaves, stock takes a mysterious and prolonged dive. Big time, in-your-facescaram(o)uche-2/14/2006
654Kosan's Chief Executive Officer Resigns Tuesday February 14, 6:45 pm ET Robedr.praveen-2/14/2006
653[Structure elucidation of new ascomycins produced by genetic engineering] >&tuck-2/11/2006
652[Sensitization of TRAIL–resistant cells by inhibition of HSP90 with low-dose geltuck-2/8/2006
651"The Epothilone Dilemma" jco.org Thanks to rfj1862 of IHub for the dtuck-2/8/2006
650I was going to comment last week, but didn't.... modest blocks going off,scaram(o)uche-2/6/2006
649That's interesting. Often a precursor to a merger. Peter (no current positiBiomaven-2/6/2006
648Item 1.01 Entry into a Material Definitive Agreement 1. Change in Control and SIcebrg-2/6/2006
647[Inhibition of Survivin followed by 17-AAG versus prostate cancer] >>Mol tuck-1/25/2006
646Kosan Initiates Phase I Clinical Trial of Oral Hsp90 Inhibitor KOS-1022 Wednesdanigel bates-1/25/2006
645[17AAG followed by TNF or TRAIL treatment for lung cancer] >>Cancer Res. tuck-1/22/2006
644Searching on "taxol and discodermolide" in pubmed gets some hits that tuck-1/18/2006
643[23,24-dihydrodiscodermolide analogues with simplified lactone regions] >>tuck-1/18/2006
642Strange buys, as he already owns between 3.6 and 3.7 million shares. So, anotherIcebrg-1/16/2006
641Dr. Santi recently added 20,000 shares to his trust accounts with open market putuck-1/16/2006
640thanks George for your milestone update..I found this private company while doinzeta1961-1/7/2006
639waiting on: KOS-862 (Epothilone D, a polyketide product that exhibits the same mopgcw-1/7/2006
638Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trIcebrg-1/1/2006
637[V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in respotuck-12/23/2005
636Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiatIcebrg-12/22/2005
635Vernalis says due 1.5 mln usd milestone payment from Novartis LONDON (AFX) - Vernigel bates-12/19/2005
634NeuTec Pharma completes patient recruitment in breast cancer clinical trial usinnigel bates-12/15/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News